- Home
- GERN vs PRG Comparison
GERN vs PRG Comparison
Compare GERN & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- PRG
- Stock Information
- Founded
- GERN 1990
- PRG 2020
- Country
- GERN United States
- PRG United States
- Employees
- GERN N/A
- PRG N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- PRG Diversified Commercial Services
- Sector
- GERN Health Care
- PRG Consumer Discretionary
- Exchange
- GERN Nasdaq
- PRG Nasdaq
- Market Cap
- GERN 2.5B
- PRG 2.0B
- IPO Year
- GERN 1996
- PRG N/A
- Fundamental
- Price
- GERN $3.66
- PRG $47.71
- Analyst Decision
- GERN Strong Buy
- PRG Buy
- Analyst Count
- GERN 10
- PRG 6
- Target Price
- GERN $6.95
- PRG $53.00
- AVG Volume (30 Days)
- GERN 9.5M
- PRG 415.8K
- Earning Date
- GERN 11-07-2024
- PRG 10-23-2024
- Dividend Yield
- GERN N/A
- PRG 1.01%
- EPS Growth
- GERN N/A
- PRG 8.67
- EPS
- GERN N/A
- PRG 3.58
- Revenue
- GERN $29,480,000.00
- PRG $2,417,577,000.00
- Revenue This Year
- GERN $30,930.80
- PRG $2.94
- Revenue Next Year
- GERN $315.72
- PRG $6.29
- P/E Ratio
- GERN N/A
- PRG $13.32
- Revenue Growth
- GERN 9199.68
- PRG N/A
- 52 Week Low
- GERN $1.64
- PRG $26.39
- 52 Week High
- GERN $5.34
- PRG $50.28
- Technical
- Relative Strength Index (RSI)
- GERN 29.99
- PRG 54.29
- Support Level
- GERN $3.98
- PRG $48.07
- Resistance Level
- GERN $4.50
- PRG $49.90
- Average True Range (ATR)
- GERN 0.21
- PRG 1.38
- MACD
- GERN -0.05
- PRG 0.35
- Stochastic Oscillator
- GERN 3.45
- PRG 71.26
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The Company has two reportable segments: (i) Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and (ii) Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the progressive leasing segment.